



**U.S. Food and Drug Administration**



**CENTER FOR DRUG EVALUATION AND RESEARCH**

[FDA Home Page](#) | [CDER Home Page](#) | [CDER Site Info](#) | [Contact CDER](#) | [What's New @ CDER](#)

[CDER Home](#) | [About CDER](#) | [Drug Information](#) | [Regulatory Guidance](#) | [CDER Calendar](#) | [Specific Audiences](#) | [CDER Archives](#)

Search   powered by 

## Information on Gadolinium-Containing Contrast Agents

The U.S. Food and Drug Administration (FDA) has asked manufacturers to include a new boxed warning on the product labeling of all gadolinium-based contrast agents which are used to enhance the quality of magnetic resonance imaging (MRI).


- [Information for Healthcare Professionals](#) [[PDF](#)] [[HTML](#)]
- [FDA News](#)
- [Questions and Answers](#)

Gadolinium-Containing Contrast Agents: Labeling and Regulatory History from Drugs@FDA

- [Gadobenate Dimeglumine \(marketed as MultiHance\)](#)
- [Gadodiamide \(marketed as Omniscan\)](#)
- [Gadopentetate Dimeglumine \(marketed as Magnevist\)](#)
- [Gadoteridol \(marketed as ProHance\)](#)
- [Gadoversetamide \(marketed as OptiMARK\)](#)

### [Historical Information](#)

[↑ Back to Top](#)   [↖ Back to Drug Index](#)

 PDF requires the free [Adobe Acrobat Reader](#)

Date created: June 8, 2006; updated May 23, 2007

[CDER Home Page](#) | [CDER Site Info](#) | [Contact CDER](#) | [What's New @ CDER](#)  
[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#) | [Privacy](#) | [Accessibility](#) | [HHS Home Page](#)

FDA/Center for Drug Evaluation and Research